(Q33632628)

28 July 2017

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies (English)

1 reference

28 July 2017

1 reference

1 reference

James Lewis Abbruzzese

10

object named as

James L Abbruzzese

1 reference

28 July 2017

Milind M Javle

1

1 reference

28 July 2017

Rachna T Shroff

2

1 reference

28 July 2017

Henry Xiong

3

1 reference

28 July 2017

Gauri A Varadhachary

4

1 reference

28 July 2017

David Fogelman

5

1 reference

28 July 2017

Shrikanth A Reddy

6

1 reference

28 July 2017

Darren Davis

7

1 reference

28 July 2017

Yujian Zhang

8

1 reference

28 July 2017

Robert A Wolff

9

1 reference

28 July 2017

language of work or name

English

0 references

publication date

14 July 2010

1 reference

28 July 2017

1 reference

28 July 2017

10

1 reference

28 July 2017

368

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-10-368

28 July 2017

0 references

cites work

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

Targeting the molecular target of rapamycin (mTOR).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2910694

PI3K/Akt pathway mutations in retinoblastoma.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-368

A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-368

Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-368

A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-368

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-368

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-368

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-368

21 January 2018

Identifiers

DOI

10.1186/1471-2407-10-368

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference